A groundbreaking study released by the Longevity Institute in Boston has confirmed that a new NAD+ based compound has successfully reversed biological markers of aging by up to 10 years in a 6-month trial. “We aren’t just slowing down aging; we are reversing it,” says the lead researcher. The FDA is fast-tracking the drug for public release by late 2027.
